Articles related to LIVER CANCER
Smartest Doc: September Quiz Questions
Questions run across a host of topics, and in September you can challenge yourself in mortality risk, myocardial infarction (MI), insomnia, liver cancer, lipids, and Parkinson’s disease guidelines. Each question is worth 4 points with bonuses for quick response. Speed matters in this quiz. Why not give it a try and see if you can get on the leaderboard of the Smartest Doc?
Allergy & Immunology September 6th 2022
ICIs Appear Safer Than TKIs for Advanced Hepatocellular Carcinoma
The meta-analysis included data from nearly 13,000 patients across 30 published trials. Grade 3 or 4 AEs occurred in nearly 70% of patents receiving TKIs compared with 37% for those receiving ICIs.
Oncology, Medical August 16th 2022
The Journal of Nuclear Medicine (JNM)
90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study
In patients with NETs with distant metastasis, 90Y radioembolization (90Y RE) might be an important treatment option; however, data to support clinical benefits are scarce. The authors purposed to analyze the use of 90Y RE in NET patients with hepatic metastases in an international, multicenter retrospective analysis. In reviewing response data, they conclude that 90Y RE could be an important alternative to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver-dominant disease pretreated with somatostatin analogs.
Oncology, Medical May 31st 2022
10-year review of health insurance data set reveals possible protective effect of H1 antihistamines in preventing hepatic cancer
Antihistamine use in patients with HBV, HCV, or dual virus infections was associated with approximately two-fold lower risk of HCC when compared with patients who did not use antihistamines, in a dose-dependent manner.
Oncology, Medical May 10th 2022
Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma (HCC)
Recently, the ALBI (albumin-bilirubin) score has been developed as an HCC-specific refinement of the Child-Pugh (C-P) score. In this commentary, the authors summarize the limitations of the C-P score, which include subjectivity and inconsistency of versions, as well as lack of sensitivity in patients with mild liver dysfunction. In comparison, the ALBI score “is entirely objective, obviating any need for subjective assessment of clinical signs, that it is derived from an entirely HCC population and is a continuous score that readily lends itself for assessment of changes in liver reserve over time.”
Oncology, Medical April 5th 2022
Treatment Approaches for Advanced Hepatocellular Carcinoma: Insight From the 2022 Gastrointestinal Cancers Symposium
A potentially practice-changing clinical trial for first line therapy is the first to show that the combination of two immunotherapy medications is an effective treatment for hepatocellular carcinoma (HCC). The HIMALAYA study evaluated combination immunotherapy (IO-IO), durvalumab with tremelimumab, as frontline therapy in patients with unresectable HCC. Overall survival was significantly improved with the IO-IO combination compared with sorafenib monotherapy (16.4 vs 13.8 months; hazard ratio [HR], 0.78; 96% CI, 0.65-0.92; P =.0035). Early results of the phase three LAUNCH trial are also promising. This trial compared the combination of lenvatinib with transarterial chemoembolization (TACE) to lenvatinib alone in an Asian population with advanced HCC. The lenvatinib-TACE group achieved a higher median overall survival (17.8 vs. 11.5 months and median progression-free survival (10.6 vs. 6.4 months). Muhammad Shaalan Beg, MD, director for GI Medical Oncology at UT Southwestern Medical Center in Dallas summarizes these and other takeaways from emerging research on advanced HCC presented at the recent ASCO GI Symposium.
Gastroenterology March 1st 2022